Large clinical research organisations (CROs) continue to merge to create a new category of mega CROs. While these are ideally placed to serve Big Pharma, they move away from small pharma and biotech businesses, which continue to grow in importance to the UK pharma sector. This is making room for small and mid-sized CROs to become the partner of choice for these businesses.
However, the inVentiv-INC merger doesn't come as a great surprise. The large CRO category seems to be stuck between being large enough to partner with large pharma, but now have to deal with 3 super-sized competitors with more capabilities. They may also be too large to be the selection of choice for small pharma, biotech, and medical device companies.Ironically, this merger activity could be a boon for all CROs placed in the mid-size/small bucket. These CROs can continue solidifying their status as the partner of choice for small pharma/biotech/medical device.